Transthyretin stabilizer therapy increases naturally-occurring antibodies in ATTR cardiomyopathy
BACKGROUND: ) exist in humans and whether they are influenced by disease or its treatment. METHODS: using immunoassays, blotting, and binding studies. Functional activity was evaluated in a fibril formation assay. RESULTS: suppressed TTR fibril aggregation. CONCLUSIONS: Naturally-occurring TTR-targeting antibodies are present from birth, modulated by disease and therapy, and inhibit fibril formation. These findings reveal an unrecognized immune mechanism with potential relevance for ATTR-CM pathogenesis and treatment.
Authors
- Ian Gering (ORCID: https://orcid.org/0000-0003-0965-3908)
- Stephan Settelmeier
- Maximilian Steinhardt (ORCID: https://orcid.org/0000-0003-3644-9187)
- Alexander Carpinteiro (ORCID: https://orcid.org/0000-0002-3316-9166)
- Richard Dodel (ORCID: https://orcid.org/0000-0003-2044-6299)
- Vladimir Cejka (ORCID: https://orcid.org/0000-0003-4393-1772)
- Ralf Küppers (ORCID: https://orcid.org/0000-0002-6691-7191)
- Daniel Agranovski
- Alexander Ross
- Ulrike Hendgen-Cotta
- Lars Michel (ORCID: https://orcid.org/0009-0002-6122-5652)
- T Rassaf
- J K Vogel
- Sarah Waydhas
- H. Christian Reinhardt
- Caroline Morbach
- Dieter Willbold
- Stefan Störk
Institutions
- Forschungszentrum Jülich (DE)
- West Cancer Center (US)
- Amyloidosis Foundation (US)
- Universitätsklinikum Würzburg (DE)
- West German Heart and Vascular Center Essen (DE)
- Heinrich Heine University Düsseldorf (DE)
- University of Duisburg-Essen (DE)
Publication Details
- Journal
- Amyloid
- Published
- 2026-04-06
- DOI
- https://doi.org/10.1080/13506129.2026.2651299
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Deutsche Forschungsgemeinschaft
- Studienstiftung des Deutschen Volkes
- Interdisziplinäres Zentrum für Klinische Forschung, Universitätsklinikum Würzburg